Effectiveness of Probiotics, Prebiotics, and Symbiotic Supplementation in Cystic Fibrosis Patients: A Systematic Review and Meta-Analysis of Clinical Trials
Authors:
- Freiser Eceomo Cruz MosqueraFMFreiser Eceomo Cruz Mosquera
- Claudia Lorena PerlazaCPClaudia Lorena Perlaza
- Anisbed Naranjo RojasARAnisbed Naranjo Rojas
- Saray Murillo RiosSRSaray Murillo Rios
- Alejandra Carrero GallegoAGAlejandra Carrero Gallego
- Sara Isabel FischersworringSFSara Isabel Fischersworring
- Juan Sebastián RodríguezJRJuan Sebastián Rodríguez
- Yamil LiscanoYLYamil Liscano
Open Access
Abstract
Background and Objectives: Cystic fibrosis (CF), caused by CFTR gene mutations, primarily affects the respiratory and gastrointestinal systems. Microbiota modulation through probiotics, prebiotics, or synbiotics may help restore microbial diversity and reduce inflammation. This study aimed to evaluate their efficacy in CF. Materials and Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) published between 2000 and 2024 was conducted in Cochrane, ScienceDirect, Web of Science, LILAC, BMC, PubMed, and SCOPUS following PRISMA guidelines. Methodological quality was assessed using the Jadad scale, and RevMan 5.4® estimated effects on pulmonary function (FEV1), exacerbations, hospitalizations, quality of life, and inflammatory markers. Results: Thirteen RCTs (n = 552), mostly in pediatric populations, were included. Most examined probiotics (e.g., Lactobacillus rhamnosus GG, L. reuteri), while four used synbiotics. Several studies reported reduced fecal calprotectin and proinflammatory interleukins (e.g., IL-6, IL-8), suggesting an anti-inflammatory effect. However, no significant differences were observed regarding hospitalizations or quality of life. Additionally, none of the studies documented serious adverse events associated with the intervention. The meta-analysis showed no significant decrease in exacerbations (RR = 0.81; 95% CI = 0.48–1.37; p = 0.43) or improvements in FEV1 (MD = 4.7; 95% CI = −5.4 to 14.8; p = 0.37), even in subgroup analyses. Sensitivity analyses did not modify the effect of the intervention on pulmonary function or exacerbation frequency, supporting the robustness of the findings. Conclusions: Current evidence suggests that probiotics or synbiotics yield inconsistent clinical benefits in CF, although some reduction in inflammatory markers may occur. Larger, multicenter RCTs with longer follow-up are needed for clearer conclusions. Until more definitive evidence is available, these supplements should be considered experimental adjuncts rather than standard interventions for CF management.Keywords
Funding Information
- Dirección General de Investigaciones of Universidad Santiago de Cali (DGI-01-2025)
This publication has 71 references indexed in Scilit:
- The effect of Lactobacillus reuteri on pulmonary function test and growth of cystic fibrosis patientsJournal of the Science of Food and Agriculture, 2024
- Cystic FibrosisJAMA, 2023
- The effect of probiotic administration on metabolomics and glucose metabolism in CF patientsPediatric Pulmonology, 2022
- A new era for people with cystic fibrosisEuropean Journal of Pediatrics, 2021
- Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of InterventionsCochrane Database of Systematic Reviews, 2019
- Clinical effects of probiotics in cystic fibrosis patients: A systematic reviewClinical Nutrition ESPEN, 2017
- Cystic fibrosis: a clinical viewCellular and Molecular Life Sciences, 2016
- Epidemiology of Cystic FibrosisClinics in Chest Medicine, 2016
- Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: A pilot studyPediatric Pulmonology, 2010
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996